European Drug Report 2020: Key Issues


This report, available in 24 languages, presents a summary of some the main findings of the 'European Drug Report 2020: Trends and Developments the EMCDDA’s latest analysis of the drug situation in Europe. The issues selected here have been chosen for their policy relevance and general interest.

Table of contents

Take our survey!
Feedback from our audiences is very valuable to us. We would like to invite you to answer our short survey on this publication. It should take no more than 5 minutes and is completely anonymous. You feedback would be greatly appreciated! Go to the survey >>

Table of contents

  • Introductory note
  • Acknowledgements
  • COVID-19 pandemic and the drug situation
  • Europe's drug situation up to 2020: Key issues identified
    • Large drug shipments are increasingly intercepted
    • Cocaine’s role in Europe’s drug problem is increasing
    • The potential for increased heroin use and existing  harms raise concerns
    • Understanding the public health impact of high-potency  cannabis and new products
    • Increased and diverse drug production within Europe
    • Continuing availability of high-strength MDMA products  highlights need for greater user awareness
    • Growing complexity in the drug market poses regulatory  challenges and health risks
    • New tools and innovative strategies are needed to support  the scaling-up of hepatitis C treatment
    • Drug overdose is increasingly associated with  an ageing population
    • New psychoactive substances have become  a more persistent problem
    • Appearance of new synthetic opioids is a worrying example  of continuing market adaptability
  • Annex: National data tables